FERRARI, ELENA
FERRARI, ELENA
Dipartimento di Scienze Farmacologiche e Biomolecolari Rodolfo Paoletti
Rabphilin-3A as a novel target to reverse α-synuclein-induced synaptic loss in Parkinson's disease
2022 E. Ferrari, D. Scheggia, E. Zianni, M. Italia, M. Brumana, L. Palazzolo, C. Parravicini, A. Pilotto, A. Padovani, E. Marcello, I. Eberini, P. Calabresi, M. Diluca, F. Gardoni
β-Glucocerebrosidase Deficiency Activates an Aberrant Lysosome-Plasma Membrane Axis Responsible for the Onset of Neurodegeneration
2022 G. Lunghi, E.V. Carsana, N. Loberto, L. Cioccarelli, S. Prioni, L. Mauri, R. Bassi, S. Duga, L. Straniero, R. Asselta, G. Soldà, A. Di Fonzo, E. Frattini, M. Magni, N. Liessi, A. Armirotti, E. Ferrari, M. Samarani, M. Aureli
NMDA and AMPA Receptors at Synapses: Novel Targets for Tau and α-Synuclein Proteinopathies
2022 M. Italia, E. Ferrari, M. Diluca, F. Gardoni
Synaptic neurofilaments and GluN1-NfL interaction in experimental models of α-synucleinopathies
2022 A. Imarisio, E. Ferrari, A. Pilotto, M. Di Luca, A. Padovani, F. Gardoni
IDENTIFICATION OF PHARMACOLOGICAL APPROACHES BLOCKING ALPHA-SYNUCLEIN SYNAPTIC TOXICITY
2021 E. Ferrari
GluA3-containing AMPA receptors: From physiology to synaptic dysfunction in brain disorders
2021 M. Italia, E. Ferrari, M. Di Luca, F. Gardoni
From cell lines to pluripotent Stem Cells for Modelling Parkinson's Disease
2020 E. Ferrari, A. Cardinale, B. Picconi, F. Gardoni
Protease-activated receptor 1 (PAR1) inhibits synaptic NMDARs in mouse nigral dopaminergic neurons
2020 R. Price, E. Ferrari, F. Gardoni, N.B. Mercuri, A. Ledonne